Top-News

Asterias Biotherapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A115BK
ISIN: US04624N1072
Typ: Aktie

Asterias Biotherapeutics News

08.11.18 - PR Newswire
Wolf Popper LLP Investigates the Proposed Acquisition of Asterias Biotherapeutics, Inc. by BioTime, Inc.
Wolf Popper LLP Investigates the Proposed Acquisition of Asterias Biotherapeutics, Inc. by BioTime, Inc. PR Newswire
17.07.17 - PR Newswire
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort Twenty patients have been enrolled in SCiStar study 20 million cell dose ...
12.07.17 - PR Newswire
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort First enrolled cohort comprised of patients with motor complete, sensory ...
10.07.17 - PR Newswire
Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study
Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study Ability to enroll patients with second most common cervical spinal cord injury broadens ...
13.06.17 - PR Newswire
Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1
Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias' AST-OPC1 Third patient recovers two motor ...
08.06.17 - PR Newswire
Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting
Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting PR ...
23.05.17 - PR Newswire
Asterias Biotherapeutics Announces Top Leadership Transition
Asterias Biotherapeutics Announces Top Leadership Transition -Steve Cartt to transition out as President & CEO, remain on the Board of Directors- -Michael Mulroy appointed ...
11.05.17 - PR Newswire
Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress -Continued positive interim efficacy and safety results reported during the ...
11.05.17 - PR Newswire
New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord ...
04.05.17 - PR Newswire
Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017
Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017 PR Newswire
03.05.17 - PR Newswire
Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury PR ...
26.04.17 - PR Newswire
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer' -57% of AML patients treated with AST-VAC1, ...
25.04.17 - PR Newswire
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal Cord Injury
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal ...
28.03.17 - PR Newswire
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress - Recent clinical trial results highlight the ...
21.03.17 - PR Newswire
Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
Update on Full Six-​Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment -Newly ...
07.03.17 - PR Newswire
Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017 PR Newswire
03.02.17 - PR Newswire
Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position - Warrant extension follows positive recent update on further motor ...
24.01.17 - PR Newswire
Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries -...
18.01.17 - PR Newswire
Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study
Asterias Announces Conference Call to Discuss 6-month Efficacy Data from AST-OPC1 SCiStar Study PR Newswire
09.01.17 - PR Newswire
Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1
Asterias Announces Successful Commencement of Operations at New GMP Manufacturing Facility for AST-OPC1 -Recent success of start-up and validation activities will enable ...

Newssuche

Videos

08:50 Uhr +2,49%
Technical Trading: AUD/USD mit Mega Chance
AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »